EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSMOCG00000015750
Gene Symbol: ATP1A3
3 Cross references
134 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSMOCG00000007734
Gene Symbol: ATP1B1
3 Cross references
294 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSMOCG00000009972
Gene Symbol: ATP1B2
3 Cross references
274 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSMOCG00000007305
Gene Symbol: ATP1B3
3 Cross references
298 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSMOCG00000015022
Gene Symbol: ATR
3 Cross references
206 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSMOCG00000014019
Gene Symbol: AXL
3 Cross references
197 Possible Orthologues:

B Cell Leukemia/lymphoma 2

Ensembl ID : ENSMOCG00000015172
Gene Symbol: BCL2
1 Cross references
227 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMOCG00000023027
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSMOCG00000004890
Gene Symbol: BCL2L1
3 Cross references
287 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSMOCG00000017284
Gene Symbol: BCL2L10
2 Cross references
129 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSMOCG00000020282
Gene Symbol: BCR
3 Cross references
274 Possible Orthologues:

Bruton Agammaglobulinemia Tyrosine Kinase

Ensembl ID : ENSMOCG00000013600
Gene Symbol: BTK
1 Cross references
206 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).